Key Findings Reviewed From ALCYONE Trial in Myeloma
Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib, melphalan, and prednisone in combination with daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible.
Maria-Victoria Mateos, MD, PhD, a physician and director of the myeloma program at the University of Salamanca, Spain, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib (Velcade), melphalan, and prednisone (VMP) in combination with daratumumab (Darzalex; DARA; D-VMP) in patients with newly diagnosed multiple myeloma who are transplant ineligible.
After a median follow-up of 28 months, D-VMP was superior to VMP in terms of overall response rate, complete response rate, and progression-free survival (PFS), Mateos says. PFS acted as a surrogate marker for overall survival.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
